Your browser doesn't support javascript.
loading
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.
Buchholz, M; Majchrzak-Stiller, B; Hahn, S; Vangala, D; Pfirrmann, R W; Uhl, W; Braumann, C; Chromik, A M.
Affiliation
  • Buchholz M; Division of Molecular and Clinical Research, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. marie.buchholz-a7y@rub.de.
  • Majchrzak-Stiller B; Division of Molecular and Clinical Research, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Hahn S; Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany.
  • Vangala D; Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany.
  • Pfirrmann RW; Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
  • Uhl W; Geistlich Pharma AG, Wolhusen, Switzerland.
  • Braumann C; Division of Molecular and Clinical Research, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Chromik AM; Division of Molecular and Clinical Research, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
BMC Cancer ; 17(1): 216, 2017 03 24.
Article in En | MEDLINE | ID: mdl-28340556
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Thiadiazines / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2017 Type: Article Affiliation country: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Thiadiazines / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2017 Type: Article Affiliation country: Germany